
For Research Use Only

CoraLite®594-conjugated GFAP Monoclonal antibody Catalog Number:CL594-60190 1 Publications



Basic Information	Catalog Number: CL594-60190	GenBank Accession Number: BC013596	Purification Method: Protein A purification	
	Size:	GeneID (NCBI):	CloneNo.:	
	100ul , Concentration: 1000 ug/ml by		4B2E10	
	Nanodrop;	UNIPROT ID:	Recommended Dilutions:	
	Source:	P14136	IF-P 1:50-1:500	
	Mouse	Full Name:	Excitation/Emission maxima	
	Isotype:	8	wavelengths:	
	lgG2a		588 nm / 604 nm	
	Immunogen Catalog Number: AG10452			
Applications	Tested Applications:	Positive Controls:		
	IF-P	IF-P : rat brain tissue,		
	Cited Applications: IF			
	Species Specificity: human, mouse, rat, pig			
	Cited Species: mouse			
	astrocytes and has been proposed as strength, and in mitosis. Tissue specif astrocytes. GFAP is commonly used a non-CNS cells, including fibroblasts, or	playing a role in cell migration, ce ficity GFAP is expressed in central s an astrocyte marker. However, G chondrocytes, lymphocytes, and liv	nervous system cells, predominantly in FAP is also present in peripheral glia and ir ver stellate cells (PMID: 21219963).	
	astrocytes and has been proposed as strength, and in mitosis. Tissue specif astrocytes. GFAP is commonly used a non-CNS cells, including fibroblasts, of Involvement in disease Mutations in CNS disorder. The mutations present i GFAP is a hallmark of reactive astroco astrogliosis is present in many neurol (including Alzheimer's and Parkinson isoforms of GFAP that differ in the roc size. Isoform expression varies during are upregulated in reactive astrocyter regulated by phosphorylation. Six pho which are reported to control filamen	playing a role in cell migration, ce ficity GFAP is expressed in central s an astrocyte marker. However, G chondrocytes, lymphocytes, and lin n GFAP lead to Alexander disease in affected individuals are though ytes, in which GFAP is present in h logical disorders, such as stroke, v s's disease), and neurotrauma. Isof d and tail domains (PMID: 2572691 g the development and across diff s. Post-translational modifications osphorylation sites have been ide t assembly (PMID: 21219963). Cel	ell motility, maintaining mechanical nervous system cells, predominantly in iFAP is also present in peripheral glia and ir ver stellate cells (PMID: 21219963). (OMIM: 203450), an autosomal dominant t to be gain-of-function. Upregulation of nypertrophic cellular processes. Reactive arious neurodegenerative diseases forms Astrocytes express 10 different (6), which means that they differ in molecul erent subtypes of astrocytes. Not all isoform s Intermediate filament proteins are ntified in GFAP protein, at least some of	
	astrocytes and has been proposed as strength, and in mitosis. Tissue specif astrocytes. GFAP is commonly used a non-CNS cells, including fibroblasts, of Involvement in disease Mutations in CNS disorder. The mutations present if GFAP is a hallmark of reactive astroco astrogliosis is present in many neurol (including Alzheimer's and Parkinson isoforms of GFAP that differ in the roc size. Isoform expression varies during are upregulated in reactive astrocyter regulated by phosphorylation. Six pho which are reported to control filamen intermediate filaments and stains we	playing a role in cell migration, ce ficity GFAP is expressed in central s an astrocyte marker. However, G chondrocytes, lymphocytes, and lin n GFAP lead to Alexander disease in affected individuals are though ytes, in which GFAP is present in h logical disorders, such as stroke, v s's disease), and neurotrauma. Isof d and tail domains (PMID: 2572691 g the development and across diff s. Post-translational modifications osphorylation sites have been ide t assembly (PMID: 21219963). Cel	ell motility, maintaining mechanical nervous system cells, predominantly in IFAP is also present in peripheral glia and ir ver stellate cells (PMID: 21219963). (OMIM: 203450), an autosomal dominant t to be gain-of-function. Upregulation of nypertrophic cellular processes. Reactive arious neurodegenerative diseases forms Astrocytes express 10 different 16), which means that they differ in molecul erent subtypes of astrocytes. Not all isoform s Intermediate filament proteins are ntified in GFAP protein, at least some of lular localization GFAP localizes to	
Notable Publications	astrocytes and has been proposed as strength, and in mitosis. Tissue specif astrocytes. GFAP is commonly used a non-CNS cells, including fibroblasts, o Involvement in disease Mutations in CNS disorder. The mutations present i GFAP is a hallmark of reactive astrocy astrogliosis is present in many neurol (including Alzheimer's and Parkinson isoforms of GFAP that differ in the roc size. Isoform expression varies during are upregulated in reactive astrocyte regulated by phosphorylation. Six pho which are reported to control filamen intermediate filaments and stains we Ex/Em 593 nm/614 nm.	playing a role in cell migration, ce ficity GFAP is expressed in central s an astrocyte marker. However, G chondrocytes, lymphocytes, and lin n GFAP lead to Alexander disease in affected individuals are though ytes, in which GFAP is present in h logical disorders, such as stroke, v s's disease), and neurotrauma. Isof d and tail domains (PMID: 2572691 g the development and across diff s. Post-translational modifications osphorylation sites have been ide t assembly (PMID: 21219963). Cel	ell motility, maintaining mechanical nervous system cells, predominantly in iFAP is also present in peripheral glia and in ver stellate cells (PMID: 21219963). (OMIM: 203450), an autosomal dominant t to be gain-of-function. Upregulation of nypertrophic cellular processes. Reactive arious neurodegenerative diseases forms Astrocytes express 10 different (6), which means that they differ in molecula rent subtypes of astrocytes. Not all isoform s Intermediate filament proteins are ntified in GFAP protein, at least some of lular localization GFAP localizes to	
Votable Publications	astrocytes and has been proposed as astronytes. GFAP is commonly used a non-CNS cells, including fibroblasts, or livolvement in disease. Mutations in CNS disorder. The mutations present is GFAP is a hallmark of reactive astroct astrogliosis is present in many neurol (including Alzheimer's and Parkinson) isoforms of GFAP that differ in the roct size. Isoform expression varies during are upregulated in reactive astrocytes regulated by phosphorylation. Six phothich are reported to control filament intermediate filaments and stains we Ex/Em 593 nm/614 nm.	playing a role in cell migration, ce ficity GFAP is expressed in central s an astrocyte marker. However, G chondrocytes, lymphocytes, and lin n GFAP lead to Alexander disease in affected individuals are though ytes, in which GFAP is present in h logical disorders, such as stroke, v i's disease), and neurotrauma. Isof and tail domains (PMID: 2572691 g the development and across diff s. Post-translational modifications osphorylation sites have been ide t assembly (PMID: 21219963). Cel ell in astrocyte cellular processes.	ell motility, maintaining mechanical nervous system cells, predominantly in iFAP is also present in peripheral glia and in ver stellate cells (PMID: 21219963). (OMIM: 203450), an autosomal dominant t to be gain-of-function. Upregulation of hypertrophic cellular processes. Reactive arious neurodegenerative diseases forms Astrocytes express 10 different 6.6), which means that they differ in molecul erent subtypes of astrocytes. Not all isoform is Intermediate filament proteins are ntified in GFAP protein, at least some of lular localization GFAP localizes to The antibody is conjugated with CL594,	
	astrocytes and has been proposed as astronytes. GFAP is commonly used a non-CNS cells, including fibroblasts, or Involvement in disease. Mutations in CNS disorder. The mutations present is GFAP is a hallmark of reactive astrocytiss is present in many neurol (including Alzheimer's and Parkinson isoforms of GFAP that differ in the roc size. Isoform expression varies during are upregulated in reactive astrocytes regulated by phosphorylation. Six phwhich are reported to control filament intermediate filaments and stains we Ex/Em 593 nm/614 nm. Author Pub Yue Wan 365	playing a role in cell migration, ce ficity GFAP is expressed in central s an astrocyte marker. However, G chondrocytes, lymphocytes, and liv n GFAP lead to Alexander disease in affected individuals are though ytes, in which GFAP is present in h logical disorders, such as stroke, v. 's disease), and neurotrauma. Isof and tail domains (PMID: 2572691 g the development and across diffe s. Post-translational modifications osphorylation sites have been ide t assembly (PMID: 21219963). Cel ell in astrocyte cellular processes. med ID Journal 98105 Glia	ell motility, maintaining mechanical nervous system cells, predominantly in IFAP is also present in peripheral glia and in ver stellate cells (PMID: 21219963). (OMIM: 203450), an autosomal dominant t to be gain-of-function. Upregulation of hypertrophic cellular processes. Reactive arious neurodegenerative diseases forms Astrocytes express 10 different L6), which means that they differ in molecul erent subtypes of astrocytes. Not all isoform s Intermediate filament proteins are ntified in GFAP protein, at least some of lular localization GFAP localizes to The antibody is conjugated with CL594, IF	
Notable Publications	astrocytes and has been proposed as strength, and in mitosis. Tissue specif astrocytes. GFAP is commonly used a non-CNS cells, including fibroblasts, o Involvement in disease Mutations in CNS disorder. The mutations present is GFAP is a hallmark of reactive astrocy astrogliosis is present in many neurol (including Alzheimer's and Parkinson isoforms of GFAP that differ in the roc size. Isoform expression varies during are upregulated in reactive astrocyte: regulated by phosphorylation. Six phy which are reported to control filamen intermediate filaments and stains we Ex/Em 593 nm/614 nm. Author Pub Yue Wan 365	playing a role in cell migration, ce ficity GFAP is expressed in central s an astrocyte marker. However, G chondrocytes, lymphocytes, and lin n GFAP lead to Alexander disease in affected individuals are though ytes, in which GFAP is present in h logical disorders, such as stroke, v. 's disease), and neurotrauma. Isof and tail domains (PMID: 2572691 g the development and across diffi s. Post-translational modifications osphorylation sites have been ide t assembly (PMID: 21219963). Cel ell in astrocyte cellular processes. med ID Journal 98105 Glia	ell motility, maintaining mechanical nervous system cells, predominantly in IFAP is also present in peripheral glia and ir ver stellate cells (PMID: 21219963). (OMIM: 203450), an autosomal dominant t to be gain-of-function. Upregulation of hypertrophic cellular processes. Reactive arious neurodegenerative diseases forms Astrocytes express 10 different 16), which means that they differ in molecul erent subtypes of astrocytes. Not all isoform 5 Intermediate filament proteins are ntified in GFAP protein, at least some of lular localization GFAP localizes to The antibody is conjugated with CL594, IF	

Selected Validation Data



Immunofluorescent analysis of (4% PFA) fixed rat brain tissue using Coralite®594 GFAP antibody (CL594-60190, Clone: 4B2E10) at dilution of 1:200.